LAM
UTHR icon

L2 Asset Management’s United Therapeutics UTHR Stock Holding History

L2 Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.36M Buy
14,091
+2,102
+18% +$1.05M 0.79% 35
2025
Q4 		$5.84M Sell
11,989
-2,334
-16% -$1.09M 0.78% 42
2025
Q3 		$6M Buy
14,323
+5,378
+60% +$1.81M 0.87% 36
2025
Q2 		$2.57M Sell
8,945
-4,952
-36% -$1.48M 0.42% 68
2025
Q1 		$4.28M Buy
13,897
+1,320
+10% +$452K 0.88% 40
2024
Q4 		$4.44M Buy
12,577
+2,570
+26% +$945K 0.96% 35
2024
Q3 		$3.59M Buy
10,007
+7,643
+323% +$2.58M 0.97% 31
2024
Q2 		$753K Buy
2,364
+300
+15% +$79.4K 0.23% 85
2024
Q1 		$474K Buy
2,064
+79
+4% +$17.8K 0.16% 105
2023
Q4 		$436K Buy
1,985
+1,406
+243% +$324K 0.18% 99
2023
Q3 		$1.43M Sell
579
-11,438
-95% -$2.63M 0.67% 48
2023
Q2 		$2.65M Buy
12,017
+1,563
+15% +$346K 1.3% 27
2023
Q1 		$2.34M Sell
10,454
-138
-1% -$34K 1.29% 22
2022
Q4 		$2.95M Buy
10,592
+13
+0.1% +$3.28K 1.83% 12
2022
Q3 		$2.21M Buy
+10,579
New +$2.37M 1.52% 21

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

L2 Asset Management's UTHR Position: Q1 2026 in Review

L2 Asset Management increased its United Therapeutics (UTHR) stake by 18% in Q1 2026, buying an estimated $1.05M and bringing the position to 14,091 shares worth $8.36M. The position accounts for 0.79% of the portfolio, ranked #35.

L2 Asset Management first reported a position in UTHR in Q3 2022 and has held it in 15 quarters since. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • L2 Asset Management held 14,091 shares of United Therapeutics worth $8.36M as of Q1 2026.
  • L2 Asset Management bought 2,102 United Therapeutics shares in Q1 2026, an estimated $1.05M.
  • United Therapeutics made up 0.79% of L2 Asset Management's portfolio in Q1 2026, its #35 holding.
  • L2 Asset Management first reported a position in United Therapeutics in Q3 2022 and has held it in 15 quarters since.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on L2 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.